Wall Street Zen Downgrades Mineralys Therapeutics (NASDAQ:MLYS) to Sell

Mineralys Therapeutics (NASDAQ:MLYS) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other analysts have also commented on MLYS. TD Cowen began coverage on Mineralys Therapeutics in a research report on Monday, April 27th. They issued a “buy” rating for the company. Bank of America lifted their price objective on Mineralys Therapeutics from $46.00 to $51.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. HC Wainwright set a $56.00 price objective on Mineralys Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Tuesday, April 21st. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $30.00 price objective on shares of Mineralys Therapeutics in a research report on Friday, March 13th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $49.14.

Mineralys Therapeutics Price Performance

Mineralys Therapeutics stock opened at $29.54 on Friday. The stock has a 50-day simple moving average of $27.15 and a 200 day simple moving average of $33.14. Mineralys Therapeutics has a 12-month low of $12.59 and a 12-month high of $47.65. The stock has a market capitalization of $2.44 billion, a price-to-earnings ratio of -14.41 and a beta of 0.49.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.04. As a group, sell-side analysts anticipate that Mineralys Therapeutics will post -2.29 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Jon Congleton sold 75,000 shares of Mineralys Therapeutics stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $26.27, for a total transaction of $1,970,250.00. Following the transaction, the chief executive officer owned 705,051 shares in the company, valued at $18,521,689.77. The trade was a 9.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ra Capital Management, L.P. acquired 310,700 shares of the business’s stock in a transaction dated Friday, March 27th. The shares were acquired at an average price of $23.67 per share, for a total transaction of $7,354,269.00. Following the acquisition, the director directly owned 5,767,221 shares in the company, valued at $136,510,121.07. This represents a 5.69% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have sold 160,120 shares of company stock worth $4,270,828. Company insiders own 18.94% of the company’s stock.

Hedge Funds Weigh In On Mineralys Therapeutics

Institutional investors have recently modified their holdings of the business. Navalign LLC bought a new position in shares of Mineralys Therapeutics during the 4th quarter valued at about $33,000. KBC Group NV bought a new position in shares of Mineralys Therapeutics during the 1st quarter valued at about $33,000. Smartleaf Asset Management LLC lifted its holdings in shares of Mineralys Therapeutics by 198.2% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock valued at $40,000 after purchasing an additional 676 shares in the last quarter. Royal Bank of Canada lifted its holdings in shares of Mineralys Therapeutics by 262.3% during the 4th quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock valued at $56,000 after purchasing an additional 1,107 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in shares of Mineralys Therapeutics by 1,845.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company’s stock valued at $76,000 after purchasing an additional 1,993 shares in the last quarter. Institutional investors own 84.46% of the company’s stock.

Key Stories Impacting Mineralys Therapeutics

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Mineralys Therapeutics and maintained a $56 price target, which can help support investor confidence despite the earnings revisions.
• Neutral Sentiment: The firm still sees long-term earnings potential, forecasting a swing to profitability later in the decade, including $0.92 EPS in FY2029 and $3.73 EPS in FY2030.
• Negative Sentiment: HC Wainwright lowered estimates for multiple periods, including Q2 2026, Q3 2026, Q4 2026, and FY2026-FY2028, signaling a more cautious near-term outlook for earnings.
• Negative Sentiment: Wall Street Zen reportedly downgraded the stock to Sell, adding another bearish headline that may weigh on sentiment. Article Title

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.